Ticker >

Pharmaids Pharma share price

Pharmaids Pharmaceuticals Ltd.

BSE: 524572 SECTOR: Pharmaceuticals & Drugs  19k   87   5

59.00
-0.78 (-1.30%)
BSE: 26 Apr 04:01 PM

Price Summary

Today's High

₹ 60.97

Today's Low

₹ 59

52 Week High

₹ 79.23

52 Week Low

₹ 27.77

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

208.08 Cr.

Enterprise Value

195.33 Cr.

No. of Shares

3.53 Cr.

P/E

0

P/B

2.87

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  20.54

CASH

12.75 Cr.

DEBT

0 Cr.

Promoter Holding

5.64 %

EPS (TTM)

₹  -2.73

Sales Growth

-100%

ROE

-49.34 %

ROCE

-63.94%

Profit Growth

-5305.67 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-100%
3 YearNA
5 Year-100%

Profit Growth

1 Year-5305.67%
3 Year-708.5%
5 Year-277.44%

ROE%

1 Year-49.34%
3 Year-15.52%
5 Year-9.98%

ROCE %

1 Year-63.94%
3 Year-20.41%
5 Year-13.74%

Debt/Equity

0

Price to Cash Flow

-51.77

Interest Cover Ratio

-2139.34240656729

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 5.64 0
Dec 2023 9.25 0
Sep 2023 9.7 0
Jun 2023 9.94 0
Mar 2023 9.95 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of -861.233716524735 days.
  • Company has a healthy liquidity position with current ratio of 8.21616121539591.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 23.0354792028931.

 Limitations

  • The company has shown a poor profit growth of -708.504262609135% for the Past 3 years.
  • Company has a poor ROE of -15.5158987097748% over the past 3 years.
  • Company has a poor ROCE of -20.4111362397776% over the past 3 years
  • Company has negative cash flow from operations of -4.01935.
  • The company has a low EBITDA margin of -2.68012420689041% over the past 5 years.
  • Promoter stake has been decreased from 9.25% to 5.64%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 0 0 0 0 0.02
Total Expenditure 0.7 8.6 1.61 1.02 1.32
Operating Profit -0.7 -8.6 -1.61 -1.02 -1.3
Other Income 0 0 0.37 -0.26 -0.9
Interest 0 0 0 0 0
Depreciation 0.01 0 0.01 0.01 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.7 -8.61 -1.24 -1.29 -2.21
Tax 0 -2.44 0.09 -0.78 -0.58
Profit After Tax -0.71 -6.16 -1.34 -0.51 -1.63
Adjusted EPS (Rs) -0.54 -2.87 -0.62 -0.24 -0.76

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0.56 0 8.55 3.94 0
Total Expenditure 0.66 0.34 8.44 3.8 9.89
Operating Profit -0.1 -0.34 0.11 0.14 -9.89
Other Income 0.01 0 0.03 0.02 0
Interest 0 0 0 0 0
Depreciation 0.05 0.04 0.04 0.01 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.14 -0.38 0.09 0.14 -9.91
Tax 0.03 -0.41 0 0 -2.35
Net Profit -0.18 0.03 0.09 0.15 -7.56
Adjusted EPS (Rs.) -0.17 0.03 0.09 0.14 -3.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 10.27 10.27 10.27 10.27 21.44
Total Reserves -1.87 -1.84 -1.74 -1.6 0.98
Borrowings 0 0 0 0 0
Other N/C liabilities 0.06 -0.35 -0.35 -0.36 -2.71
Current liabilities 0.2 0.03 0.59 2.44 2.13
Total Liabilities 8.67 8.11 8.76 10.76 21.85
Assets
Net Block 0.08 0.08 0.04 0.03 0.11
Capital WIP 0.45 0.45 0.45 0.45 2
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 3.76 7.19 7.42 7.61 2.14
Other N/C Assets 0 0 0 0 0.12
Current Assets 4.38 0.39 0.86 2.67 17.48
Total Assets 8.67 8.11 8.76 10.76 21.85
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -0.14 -0.38 0.09 0.14 -9.91
Adjustment 0.04 0.04 0.04 0.01 0.05
Changes in Assets & Liabilities 0 -0.41 0.27 -0.41 5.84
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.1 -0.75 0.41 -0.26 -4.02
Investing Cash Flow 0 0.66 -0.23 0.47 -4.94
Financing Cash Flow -0.03 0 0 0 21.31
Net Cash Flow -0.13 -0.09 0.18 0.21 12.35

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 9.95 9.94 9.70 9.25 5.64
abhilekha jain - 0.16 0.16 0.16 0.10
b venkatswamy 0.02 0.02 0.02 0.02 0.01
ghisulal jain 0.17 0.17 0.17 0.17 0.10
kant rao 0.03 0.03 0.03 0.03 0.02
padmaja kalyani sadhanala... 0.88 0.88 0.88 0.88 0.54
pilli meena kumari 0.26 0.26 0.26 0.26 0.16
prashant h. dave 0.05 0.05 0.05 0.05 0.03
sadhanala venkata rao - 7.39 7.42 7.22 4.40
subhash b lalwani 0.15 0.15 0.15 0.15 0.09
veena lalwani 0.07 0.07 0.07 0.07 0.04
viswa prasad sadhanala 0.45 0.45 0.45 0.21 0.13
umadevi babulal jain 0.03 0.01 0.01 0.01 -
peddi anuradha 0.26 0.26 - - -
abhilekha jain 0.16 - - - -
venkata bhagi rao sadhana... 7.39 - - - -
abhilekha jain - 0.16 0.16 0.16 0.10
prashant h. dave 0.05 0.05 0.05 0.05 0.03
subhash b lalwani 0.15 0.15 0.15 0.15 0.09
umadevi babulal jain ... 0.03 0.01 0.01 0.01 -
veena lalwani 0.07 0.07 0.07 0.07 0.04
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 90.05 90.06 90.30 90.75 94.36
asian hotels - - - - 7.72
balagangadhara b c 3.03 3.03 - 3.03 1.84
gokaram ramakrishna balaj... - - - - 9.06
govindaraja setty sriniva... 3.62 3.62 3.62 2.70 1.33
makam sreevalli - - - - 2.21
mini manikantan - - - - 1.42
narasandra basavarajappa ... 5.24 5.24 5.24 5.24 3.19
s prasad - - - - 1.21
shankarappa nagaraja vina... - - - - 14.74
shreedhara shetty - - - 21.64 18.70
sukhil s mirji 3.70 3.70 3.70 3.70 2.26
tumkur trade center priva... - - - - 4.45
v mahendra - - - - 1.24
venu madhava kaparthy 4.08 4.08 4.08 4.08 2.48
m r mahadevan - 1.63 1.63 1.63 -
percy homi italiazareen i... - - 1.05 1.26 -
sachin jayant maldetejas ... 1.39 1.39 1.52 1.52 -
shankarappanagaraja vinay... 24.20 24.20 24.20 24.20 -
shreedhara shetty 21.64 21.64 21.64 - -
maliemadom ramaswamy iyer... 1.63 - - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Pharmaids Pharmaceuticals informs about disclosure26 Mar 2024, 12:48PM Pharmaids Pharmaceuticals informs about disclosure6 Mar 2024, 11:19AM Pharmaids Pharmaceuticals informs about disclosure 6 Mar 2024, 11:13AM Pharmaids Pharmaceuticals acquires 99.86% shareholding in Adita Bio Sys2 Mar 2024, 4:43PM Pharmaids Pharmaceuticals informs about allotment of equity shares2 Mar 2024, 4:24PM Pharmaids Pharmaceuticals informs about outcome for board meeting 2 Mar 2024, 3:12PM Pharmaids Pharma - Quaterly Results12 Feb 2024, 3:20PM Pharmaids Pharma - Quaterly Results12 Feb 2024, 3:20PM Pharmaids Pharma - Quaterly Results12 Feb 2024, 3:20PM Pharmaids Pharmaceuticals informs about disclosure12 Feb 2024, 3:09PM Pharmaids Pharmaceuticals informs about compliances-certificate10 Jan 2024, 5:05PM Pharmaids Pharmaceuticals informs about execution of shareholders agreement 9 Jan 2024, 9:54AM Pharmaids Pharmaceuticals gets nod to acquire stake in Adita Bio Sys8 Jan 2024, 11:42AM Pharmaids Pharmaceuticals informs about disclosure14 Dec 2023, 3:20PM Pharmaids Pharmaceuticals acquires two land parcels in Karnataka26 Sep 2023, 5:42PM Pharmaids Pharmaceuticals informs about loss of share certificate11 Sep 2023, 4:19PM Pharmaids Pharma - Quaterly Results4 Aug 2023, 2:44PM Pharmaids Pharma - Quaterly Results4 Aug 2023, 2:44PM Pharmaids Pharma - Quaterly Results4 Aug 2023, 2:44PM Pharmaids Pharmaceuticals informs about board meeting 28 Jul 2023, 12:14PM Pharmaids Pharmaceuticals informs about disclosure 21 Jul 2023, 12:41PM Pharmaids Pharmaceuticals informs about issuance of duplicate share certificate5 Jul 2023, 12:32PM Pharmaids Pharmaceuticals informs about issue of duplicate share certificate19 Jun 2023, 2:38PM Pharmaids Pharmaceuticals informs about statement of deviations or variations27 Apr 2023, 4:30PM Pharmaids Pharmaceuticals inks pact to acquire 51% stake in Anugraha Chemicals27 Jan 2023, 9:26AM Pharmaids Pharma - Quaterly Results9 Nov 2022, 12:49PM Pharmaids Pharma - Quaterly Results9 Nov 2022, 12:49PM Pharmaids Pharma - Quaterly Results9 Nov 2022, 12:49PM Pharmaids Pharmaceuticals informs about board meeting7 Oct 2022, 4:06PM Pharmaids Pharmaceuticals informs about proceedings of AGM20 Aug 2022, 3:42PM Pharmaids Pharmaceuticals informs about compliance certificate9 Aug 2022, 5:15PM Pharmaids Pharma - Quaterly Results22 Jul 2022, 1:13PM Pharmaids Pharma - Quaterly Results22 Jul 2022, 1:13PM Pharmaids Pharma - Quaterly Results22 Jul 2022, 1:13PM Pharmaids Pharmaceuticals informs about compliance certificate7 Jul 2022, 4:56PM Pharmaids Pharmaceuticals’ promoter offloads 6.98% stake7 Jun 2022, 11:20AM Pharmaids Pharmaceuticals' promoter sells 7.75% stake3 Jun 2022, 12:38PM Pharmaids Pharmaceuticals submits audited financial results21 May 2022, 3:41PM Pharmaids Pharma - Quaterly Results21 May 2022, 12:52PM Pharmaids Pharma - Quaterly Results21 May 2022, 12:52PM Pharmaids Pharma - Quaterly Results21 May 2022, 12:52PM Pharmaids Pharmaceuticals informs about compliance certificate7 Apr 2022, 4:59PM Pharmaids Pharmaceuticals informs about voting results27 Sep 2021, 4:16PM Pharmaids Pharmaceuticals informs about proceedings of AGM25 Sep 2021, 2:58PM Pharmaids Pharmaceuticals informs about board meeting15 May 2021, 4:46PM

Pharmaids Pharma Stock Price Analysis and Quick Research Report. Is Pharmaids Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Pharmaids Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Pharmaids Pharma cash from the operating activity was Rs -4.01935 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Pharmaids Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Pharmaids Pharma , the EPS growth was -2593.63057324841 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Pharmaids Pharma has OPM of 0 % which is a bad sign for profitability.
     
  • ROE: Pharmaids Pharma have a poor ROE of -49.3359957429132 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Pharmaids Pharma is Rs 59. One can use valuation calculators of ticker to know if Pharmaids Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Pharmaids Pharma
X